Ferroptosis in Osteoarthritis: Current Understanding.

IF 4.2 2区 医学 Q2 IMMUNOLOGY Journal of Inflammation Research Pub Date : 2024-11-07 eCollection Date: 2024-01-01 DOI:10.2147/JIR.S493001
Yikai Liu, Zian Zhang, Yuan Fang, Chang Liu, Haining Zhang
{"title":"Ferroptosis in Osteoarthritis: Current Understanding.","authors":"Yikai Liu, Zian Zhang, Yuan Fang, Chang Liu, Haining Zhang","doi":"10.2147/JIR.S493001","DOIUrl":null,"url":null,"abstract":"<p><p>Osteoarthritis (OA) is a prevalent degenerative disease in elderly people that is characterized by cartilage loss and abrasion, leading to joint pain and dysfunction. The aetiology of OA is complicated and includes abnormal mechanical stress, a mild inflammatory environment, chondrocyte senescence and apoptosis, and changes in chondrocyte metabolism. Ferroptosis is a regulated cell death modality characterized by the excessive accumulation of lipid peroxidation and mitochondrial dysfunction. The role of ferroptosis in OA pathogenesis has aroused researchers' attention in the past two years, and there is mounting evidence indicating that ferroptosis is destructive. However, the impact of ferroptosis on OA and how the regulators of ferroptosis affect OA development are unclear. Here, we reviewed the current understanding of ferroptosis in OA pathogenesis and summarized several drugs and compounds targeting ferroptosis in OA treatment. The accumulation of intracellular iron, the trigger of Fenton reaction, the excessive production of ROS, the peroxidation of PUFA-PLs, and mitochondrial and membrane damage are involved in chondrocyte ferroptosis. System X<sub>c</sub> <sup>-</sup> and GPX4 are the most important regulators that control ferroptosis. Several compounds, such as DFO and Fer-1, have been proven effective in preventing ferroptosis and slowing OA progression on animal models. Collectively, targeting ferroptosis shows great potential in treating OA.</p>","PeriodicalId":16107,"journal":{"name":"Journal of Inflammation Research","volume":"17 ","pages":"8471-8486"},"PeriodicalIF":4.2000,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11552513/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Inflammation Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/JIR.S493001","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Osteoarthritis (OA) is a prevalent degenerative disease in elderly people that is characterized by cartilage loss and abrasion, leading to joint pain and dysfunction. The aetiology of OA is complicated and includes abnormal mechanical stress, a mild inflammatory environment, chondrocyte senescence and apoptosis, and changes in chondrocyte metabolism. Ferroptosis is a regulated cell death modality characterized by the excessive accumulation of lipid peroxidation and mitochondrial dysfunction. The role of ferroptosis in OA pathogenesis has aroused researchers' attention in the past two years, and there is mounting evidence indicating that ferroptosis is destructive. However, the impact of ferroptosis on OA and how the regulators of ferroptosis affect OA development are unclear. Here, we reviewed the current understanding of ferroptosis in OA pathogenesis and summarized several drugs and compounds targeting ferroptosis in OA treatment. The accumulation of intracellular iron, the trigger of Fenton reaction, the excessive production of ROS, the peroxidation of PUFA-PLs, and mitochondrial and membrane damage are involved in chondrocyte ferroptosis. System Xc - and GPX4 are the most important regulators that control ferroptosis. Several compounds, such as DFO and Fer-1, have been proven effective in preventing ferroptosis and slowing OA progression on animal models. Collectively, targeting ferroptosis shows great potential in treating OA.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
骨关节炎中的铁蛋白沉积症:当前的认识。
骨关节炎(OA)是老年人中一种常见的退行性疾病,其特点是软骨流失和磨损,导致关节疼痛和功能障碍。OA 的病因复杂,包括异常机械应力、轻度炎症环境、软骨细胞衰老和凋亡以及软骨细胞新陈代谢的变化。铁凋亡是一种调节性细胞死亡模式,其特点是脂质过氧化物的过度积累和线粒体功能障碍。近两年来,铁蜕变在 OA 发病机制中的作用引起了研究人员的关注,越来越多的证据表明铁蜕变具有破坏性。然而,铁凋亡对 OA 的影响以及铁凋亡的调节因子如何影响 OA 的发展尚不清楚。在此,我们回顾了目前对OA发病机理中铁色素沉着的认识,并总结了几种在OA治疗中靶向铁色素沉着的药物和化合物。细胞内铁的积累、Fenton 反应的触发、ROS 的过量产生、PUFA-PLs 的过氧化、线粒体和膜的损伤参与了软骨细胞铁变态反应。Xc 系统和 GPX4 是控制铁变态反应最重要的调节因子。在动物模型上,DFO 和 Fer-1 等几种化合物已被证明能有效预防铁蛋白沉积并减缓 OA 的进展。总之,以铁蛋白沉积为靶点在治疗 OA 方面显示出巨大的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Inflammation Research
Journal of Inflammation Research Immunology and Microbiology-Immunology
CiteScore
6.10
自引率
2.20%
发文量
658
审稿时长
16 weeks
期刊介绍: An international, peer-reviewed, open access, online journal that welcomes laboratory and clinical findings on the molecular basis, cell biology and pharmacology of inflammation.
期刊最新文献
Chronic Inflammation and Age-Related Hearing: Based on Mendelian Randomization. Norisoboldine Reduces Arthritis Severity by Attenuating Inflammation, Oxidative Stress, and Extracellular Matrix Degradation in a Rat Model of Rheumatoid Arthritis. Predictive Value of dsDNA and Nucleosomes as Neutrophil Extracellular Traps-Related Biomarkers for COVID-19 in Older Patients. Cardamonin Attenuates Myocardial Ischemia/Reperfusion-Induced Ferroptosis Through Promoting STAT3 Signaling. Serpin B9 is Highly Expressed in Lung Adenocarcinoma and is Associated with Progression-Free Survival.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1